Viridian Therapeutics, Inc. (LON:0K1R)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 2.52B +26.6% |
| Revenue (ttm) | 19.82M -62.8% |
| Net Income | -299.48M |
| EPS | -2.85 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,558 |
| Open | 30.01 |
| Previous Close | 30.17 |
| Day's Range | 29.80 - 30.96 |
| 52-Week Range | 13.25 - 34.31 |
| Beta | 1.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Viridian Therapeutics
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED. Its portfolio of engineered inhibitors o... [Read more]
Financial Performance
In 2025, Viridian Therapeutics's revenue was $70.85 million, an increase of 23359.93% compared to the previous year's $302,000. Losses were -$281.93 million, 35.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
Viridian Therapeutics price target raised to $39 from $34 at Wells Fargo
Wells Fargo raised the firm’s price target on Viridian Therapeutics (VRDN) to $39 from $34 and keeps an Overweight rating on the shares. The firm expects further upside as strong…
Viridian Therapeutics Transcript: Study update
Subcutaneous VRDN-008 showed a 15–18-day half-life and 74% peak IgG reduction, supporting potential Q8W dosing. Plans call for a mid-2027 MG registrational trial using Q4W and Q8W arms versus placebo.
Viridian Therapeutics Press release: Study update
Viridian Therapeutics issued a press release on November 9, 2026, disclosing material business information to investors.
Viridian Therapeutics Slides: Study update
Viridian Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 9, 2026.
Viridian Therapeutics announces phase 1 results for VRDN-008
Viridian Therapeutics (VRDN) announced positive phase 1 results for VRDN-008. Key highlights: VRDN-008, a half-life extended FcRn inhibitor, demonstrated deep and sustained IgG reduction through 8 wee...
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoi...
Viridian Therapeutics Slides: Corporate presentation
Viridian Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 9, 2026.
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for aut...
Viridian Therapeutics price target raised to $33 from $26 at Evercore ISI
Evercore ISI raised the firm’s price target on Viridian Therapeutics (VRDN) to $33 from $26 and keeps an Outperform rating on the shares.
Viridian Therapeutics price target raised to $40 from $22 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Viridian Therapeutics (VRDN) to $40 from $22 and keeps a Buy rating on the shares. The company’s Q3 “marked a clean commercial…
Viridian Therapeutics price target raised to $53 from $40 at Goldman Sachs
Goldman Sachs analyst Richard Law raised the firm’s price target on Viridian Therapeutics (VRDN) to $53 from $40 and keeps a Buy rating on the shares after its better-than-expected Q3…
Viridian Therapeutics Earnings Call Transcript: Q3 2026
Lumvoa generated $24.7M in its first launch quarter, with 100+ patients treated and $955M+ in cash and securities. Payer coverage and pipeline programs are advancing, while management cautioned that launch trends remain early.
Viridian Therapeutics Earnings release: Q3 2026
Viridian Therapeutics released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Viridian Therapeutics Quarterly report: Q3 2026
Viridian Therapeutics has published its Q3 2026 quarterly earnings report on November 4, 2026.
Viridian Therapeutics Slides: Q3 2026
Viridian Therapeutics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Viridian Therapeutics reports Q3 EPS (81c), consensus ($1.02)
Reports Q3 revenue $25.7M vs. $70.6M last year “We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations,” said Steve Mahoney, President and…
Viridian Therapeutics sees cash runway through profitability
Cash, cash equivalents, and marketable securities were $955.2 million as of September 30, 2026. Existing cash and anticipated future commercial revenues from Lumvoa and elegrobart, if approved, are ex...
Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for aut...
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for aut...
Viridian Therapeutics price target raised to $38 from $36 at RBC Capital
RBC Capital raised the firm’s price target on Viridian Therapeutics (VRDN) to $38 from $36 and keeps an Outperform rating on the shares. The firm has spoken to 6 TED…
Viridian Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Lumvoa IV launch shows strong early engagement, robust demand, and operational execution, with a focus on converting TEPEZZA prescribers and expanding into chronic TED. Pipeline advances include a sub-Q BLA submission in Q1 2027, FcRn and TSHR programs, and a comprehensive strategy to address both active and chronic patient populations.
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for aut...
Viridian Therapeutics price target raised to $39 from $38 at Truist
Truist raised the firm’s price target on Viridian Therapeutics (VRDN) to $39 from $38 and keeps a Buy rating on the shares.
Viridian Therapeutics price target raised to $36 from $35 at RBC Capital
RBC Capital analyst Lisa Walter raised the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $35 and keeps an Outperform rating on the shares.
Viridian Therapeutics reports EPS ($1.05), consensus ($1.03)
Reports revenue $284,000 vs. $75,000 last year”We are very encouraged by the early indications from our recent launch of Lumvoa as we start a new chapter for Viridian as a…